



Drug Development for Infectious Diseases

Guest Editors:

Dr. Debora Decote-Ricardo

Dr. Marco Edilson Freire De Lima

Dr. Lucia Pinto da Silva

Dr. Célio Geraldo Freire-de-Lima

Deadline for manuscript
submissions:
closed (31 December 2023)

Message from the Guest Editors

Infectious diseases are caused by microorganisms (protozoa, bacteria, helminths, fungi and virus) with a complex life cycle that sometimes involves more than one host. They present significant morbidity and mortality rates that can impact the life expectancy of humans and animals. Although they can be present in several parts of the world, they are prevalent in South America, Central America, Africa and Asia. The most affected populations are those with lower purchasing power and those in precarious sanitary conditions. Although some have already been described hundreds of years ago, for most of them, there are no effective chemotherapeutics. Thus, the search for new molecules that can eliminate or alleviate this scourge of mostly poor populations is urgent and necessary. The purpose of this Special Issue is to bring together original research articles, reviews and case reports on molecules with chemotherapeutic potential for the treatment of infectious diseases. Thus, we are interested in works about new natural or synthetic molecules or even molecules that are already known and used in other situations that can be repositioned.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Lawrence S. Young

Warwick Medical School,
University of Warwick, Coventry
CV4 7AL, UK

Message from the Editor-in-Chief

The worldwide impact of infectious disease is incalculable. The consequences for human health in terms of morbidity and mortality are obvious and vast but, when infections of animals and plants are also taken into account, it is hard to imagine any other disease that has such a significant impact on our lives—on healthcare systems, on agriculture and on world economics. *Pathogens* is proud to continue to serve the international community by publishing high quality studies that further our understanding of infection and have meaningful consequences for disease intervention.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, PubAg, CaPlus / SciFinder, AGRIS, and other databases.

Journal Rank: JCR - Q2 (*Microbiology*) / CiteScore - Q2 (*General Immunology and Microbiology*)

Contact Us

Pathogens Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pathogens
pathogens@mdpi.com
[X@Pathogens_MDPI](#)